New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
12:28 EDTOUTR, ECYT, AZN, SKX, MPEL, MRK, LNKD, WYNN, PFEOn The Fly: Midday Wrap
Stocks on Wall Street were mixed near noon, with Dow serving as the only major index in the red, after a better-than-expected jobs report was contrasted by headlines indicating rising tensions in Ukraine. The U.S. jobs reported showed the world's largest economy added 288,000 jobs in April, but amid unrest in Ukraine, U.S. Treasury bonds have continued their recent rally as investors trend towards risk-off positioning. ECONOMIC EVENTS: In the U.S., April Nonfarm Payrolls grew by 288,000, topping economists' expectations for a gain of 215,000 jobs, taking the unemployment rate down to 6.3% from 6.7%, also beating expectations for a 6.6% reading. The U.S. jobs report showed that average hours worked and average hourly wages were flat when compared to the prior month. March factory orders grew up 1.1%, which was lower than the 1.5% reading expected by economists, and lower than the prior reading of 1.6%. In Europe, the manufacturing PMI in the Euro area increased to 53.4 in April from 53.0 in March, which was a slightly better than expected increase. COMPANY NEWS: AstraZeneca (AZN) rejected the latest buyout proposal from Pfizer (PFE), which increased its offer for the British drugmaker to $84.47 per share, or about $106B. In rejecting Pfizer's offer, AstraZeneca said the bid "substantially" undervalued the company, adding that the board had no hesitation in rejecting the proposal. This bid represents the second bid from Pfizer rejected by AstraZeneca within a week, and shares of Pfizer fell about 1.5% after the news. U.S.-listed shares of AstraZeneca were unchanged near noon... Also in the pharmaceutical space, Merck (MRK) and Endocyte (ECYT) announced that the safety board monitoring their Phase 3 PROCEED trial of their ovarian cancer drug candidate vintafolide recommended stopping the trial due to futility. Endocyte said that after completing the trial, Merck will be responsible for the development of vintafolide going forward, and shares of Endoctye were down about 60% near noon, while shares of Merck were down 2.5%. MAJOR MOVERS: Among the notable gainers was Wynn Resorts (WYNN), up 6% near noon after last night reporting earnings and revenue that topped expectations, with its revenue in Macau growing 14%. Shares of several casino peers, notably Melco Crown (MPEL), which operates casinos based in Macau, climbed following Wynn's report. Also higher was Redbox operator Outerwall (OUTR), up 6.5% after its fiscal 2014 outlook topped expectations. Among the noteworthy losers was professional networking site LinkedIn (LNKD), down about 5% after last night giving second quarter and fiscal 2014 revenue outlooks that disappointed. Also lower was Skechers (SKX), down 4% near noon after announcing plans to explore acquiring an interest in the Los Angeles Clippers. INDEXES: Near midday, the Dow was down 14.32, or 0.09%, to 16,544.55, the S&P 500 was up 0.91, or 0.05%, to 1,884.59, and the Nasdaq was up 6.76, or 0.16%, to 4,134.21.
News For AZN;PFE;MRK;ECYT;WYNN;MPEL;OUTR;LNKD;SKX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZN, PFE, MRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
08:00 EDTSKXSkechers announces three-for-one stock split subject to investor approval
SKECHERS USA announced that its Board of Directors has approved a three-for-one split of the Company's Class A and Class B common stock that will be distributed in the form of a stock dividend. The stock split is subject to stockholder approval of an amendment to the Company's Certificate of Incorporation to increase the authorized number of Class A and Class B shares. The stockholder vote is expected to take place at a special meeting of stockholders currently scheduled for September 24, 2015. If the Company's stockholders approve the authorization of additional shares, the stock dividend will be distributed to the stockholders of record as of the close of business on October 2, 2015, with a payment date of October 15, 2015. "Our decision to adopt this stock split is another indication of our confidence in our business model worldwide, which we believe will continue to generate profitable growth and strong cash flows," stated Robert Greenberg, Skechers CEO. "We are looking forward to continuing to deliver our broad-based collection of men's, women's and kids' footwear to the global market. Personally, I have never been more confident and excited about the future of Skechers."
07:17 EDTWYNN, MPELMacau developments negative, says Wells Fargo
Wells Fargo says that its checks on Macau for August indicate that the region's revenues are trending flat to down this month. According to Wells, in August the region's revenues are historically up 4% versus July. The firm adds that comments by Macau casino owner Galaxy suggest that the market has not yet bottomed. Wells believes that the market has not yet stabilized and remains neutral on Macau stocks, although it remains upbeat on their long-term outlook. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Melco Crown (MPEL) and Wynn Resorts (WYNN).
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRK, AZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
10:22 EDTLNKDAfter meeting with CEO, JPMorgan says buy LinkedIn
After meeting with LinkedIn's CEO Jeff Weiner and CFO Steve Sordello, JPMorgan tells investors to buy the stock. Calling the recent decline in the shares a buying opportunity, the firm is upbeat about the outlook for the company's Talent, Marketing, and Sales Navigation units. WHAT'S NEW: Talent has performed well since the company assigned new sales professionals to most of its accounts in the first quarter, JPMorgan analyst Doug Anmuth quoted LinkedIn as saying. Additionally, the company improved Talent by enabling users to search by key criteria such as hiring volume and overall spending potential, Anmuth believes. Meanwhile, LinkedIn is improving Marketing by replacing display ads with sponsored updates which have higher click through rates and pricing, the analyst added. As a result of this change, Marketing's growth could reaccelerate in 2016, Anmuth contended. Additionally, LinkedIn's recently acquired online learning website, Lynda.com, is "just beginning to ramp," and its Sales Navigation unit is poised to make bigger deals with corporations, Anmuth believes. The analyst kept a $300 price target and Overweight rating on the shares. WHAT'S NOTABLE: On August 13, research firm Stifel called LinkedIn its "best emerging large cap idea." The firm expects positive catalysts to emerge for the company in the second half of 2015. It kept a Buy rating on the shares. PRICE ACTION: In early trading, LinkedIn lost 0.7% to $188.
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
06:57 EDTLNKDLinkedIn pullback a buying opportunity, says JPMorgan
JPMorgan analyst Doug Anmuth recommends using the recent pullback in shares of LinkedIn as a buying opportunity. After meeting with management, including CEO Jeff Weiner and CFO Steve Sordello, Anmuth reiterates an Overweight rating on the stock. Management's tone was upbeat as Talent metrics have improved, the analyst points out. He keeps a $300 price target on the name.
06:45 EDTSKXSkechers volatility increases as shares near record high
Skechers August call option implied volatility is at 40, September is at 36; compared to its 52-week range of 27 to 58, suggesting non-directional price movement.
August 19, 2015
07:54 EDTLNKDLinkedIn management to meet with Pacific Crest
Meeting to be held on the West Coast on August 25 hosted by Pacific Crest.
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
07:13 EDTMPEL, WYNNMacau GGR poised to sink 37% in August, says Bernstein
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use